Review



integrin β4  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology integrin β4
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Integrin β4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 136 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/Integrin+%CE%B24+Antibody/pmc13025033-274-5-13
    Average 93 stars, based on 136 article reviews
    integrin β4 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity"

    Article Title: Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity

    Journal: Science Advances

    doi: 10.1126/sciadv.aeb5894

    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Figure Legend Snippet: ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].

    Techniques Used: Activation Assay, Construct, Expressing, Western Blot, Confocal Microscopy, Incubation, FLAG-tag

    Related Articles

    Blocking Assay:

    Article Title: Laminin-defined mechanical status modulates retinal pigment epithelium phagocytosis.
    Article Snippet: .. The following azide-free blocking antibodies were used: integrin β1 (clone P5D2) (Santa Cruz, sc-13590 L), integrin β4 (clone ASC-8) (Merk, MAB2059Z), integrin αvβ3 (clone LM609) (Merk, MAB1976Z), integrin α3 (clone P1B5) (Merk, MAB1952Z), integrin α5 (clone P1D6) (Merk, MAB1956Z), integrin α6 (clone GOH3) (Santa Cruz, sc-19622 L). .. One-week-old iRPE cells were carefully detached from the hydrogel substrate by incubation with 10mM EDTA in PBS−/− at 37 °C and 5% CO2 for 30min, followed by Accutase solution (Sigma-Aldrich, A6964) for 15min.

    Article Title: Laminin-defined mechanical status modulates retinal pigment epithelium phagocytosis
    Article Snippet: .. The following azide-free blocking antibodies were used: integrin β1 (clone P5D2) (Santa Cruz, sc-13590 L), integrin β4 (clone ASC-8) (Merk, MAB2059Z), integrin αvβ3 (clone LM609) (Merk, MAB1976Z), integrin α3 (clone P1B5) (Merk, MAB1952Z), integrin α5 (clone P1D6) (Merk, MAB1956Z), integrin α6 (clone GOH3) (Santa Cruz, sc-19622 L). .. One-week-old iRPE cells were carefully detached from the hydrogel substrate by incubation with 10 mM EDTA in PBS −/− at 37 °C and 5% CO 2 for 30 min, followed by Accutase solution (Sigma-Aldrich, A6964) for 15 min. During this period, gentle shaking was beneficial for detachment.

    other:


    Control:

    Article Title: Integrin α6β4 Upregulates PTPRZ1 Through UCHL1-Mediated Hif-1α Nuclear Accumulation to Promote Triple-Negative Breast Cancer Cell Invasive Properties
    Article Snippet: For whole cell lysate assessment, cells were harvested with RIPA buffer (150 mM NaCl, 0.5 mM EGTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM Tris-HCl pH 7.4, 15 μg/mL protease inhibitor cocktail (Millipore Sigma), 1 mM PMSF, 50 mM NaF and 10 mM sodium pyrophosphate). .. Fractionated or whole cell lysates (80 μg), as noted, were separated by 8% or 15% SDS–PAGE and then immunoblotted with various antibodies: integrin β4 (H101, cat# sc-9090), UCHL1 (C-4, cat# sc-271638, Santa Cruz, Biotechnology, Dallas, TX, USA), PTPRZ1 (cat# HPA015103, Millipore Sigma), Hif-1α (D2U3T, cat# 14179) and Hif-1β (D28F3, cat #5537) (Cell Signaling Technology, Danvers, MA, USA), and Hif-2α (cat# ab199, Abcam, Waltham, MA, USA). β-actin (MilliporeSigma) was used as a loading control for total cell lysates, tubulin (MilliporeSigma) for cytosolic fraction, and p84 (5E10, cat# GTX70220, GeneTex, Irvine, CA, USA) for nuclear extracts. ..

    Western Blot:

    Article Title: Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide
    Article Snippet: .. 2 Table S1: List of Antibodies used in the study Antibody Company Dilution AKT Cell Signaling 4685 1:1000 pAKT S473 Cell Signaling 4060 1:1000 mTOR Cell Signaling 4517 1:1000 pmTOR S2448 Cell Signaling 5536 1:1000 p70 S6 kinase Cell Signaling 9202 1:1000 pp70 S6 kinase (T389) Cell Signaling 9206 1:1000 4EBP1 Cell Signaling 9644 1:1000 p4EBP1 (T37/46) Cell Signaling 2855 1:1000 JNK1 Cell Signaling 3708 1:1000 p-SAPK/JNK (T183/Y185) Cell Signaling 9255 1:2000 P44/42 MAPK (Erk 1⁄2) Cell Signaling 9102 1:1000 pERK T202/Y204 Cell Signaling 4370 1:1000 p38 MAPK Cell Signaling 9212 1:1000 pp38 MAPK (T180/Y182) Cell Signaling 9211 1:1000 Cleaved PARP Cell Signaling 5625 1:1000 Cleaved Caspase 3 Cell Signaling 9661 1:500 Procaspase 3 Abcam ab32150 1:1000 Bim Cell Signaling 2933 1:1000 Bad Santa Cruz SC-8044 1:200 Bak Cell Signaling 12105 1:1000 Bax Santacruz SC-7480 1:500 Bcl2 Santacruz SC-578 1:500 BclXL Cell Signaling 4477 1:500 E-cadherin Cell Signaling 3195 1:1000 Slug Cell Signaling 9585 1:1000 Zeb1 Santa Cruz SC-515797 1:500 β-catenin Cell Signaling 8480 1:1000 Integrin αV Cell Signaling 4711 1:1000 Integrin β3 Cell Signaling 4702 1:1000 Integrin β4 Santa Cruz SC-6628 1:500 ILK Cell Signaling 3856 1:1000 FAK Cell Signaling 3285 1:1000 pFAK (Y397) Cell Signaling 3283 1:1000 Rac1 Abcam ab33186 1:1000 Rac1+Cdc42 Abcam ab76535 1:1000 PAK1 phospho (S144) Abcam ab40795 1:5000 PAK1 Abcam ab40852 1:500 Cofilin Cell Signaling 5175 1:1000 pCofilin (S3) Cell Signaling 3313 1:1000 pVASP S157 Cell Signaling 3111 1:1000 3 pVASP S239 Cell Signaling 3114 1:1000 Diaph1 Invitrogen PA5-21409 1:500 P44/42 MAPK (Erk 1⁄2) Cell Signaling 9102 1:1000 CDK2 Cell Signaling 2546 1:1000 pCDK2 (Thr160) Cell Signaling 2561 1:1000 Cyclin E2 Cell Signaling 4132 1:1000 γH2AX Cell Signaling 2577 1:1000 14-3-3 σ Abcam ab14123 1:1000 F-actin Abcam ab205 1:500 β-actin Sigma A2228 1:1000 4 Denistometric data for all western blots Densitometric analysis of Western blot data represented in Figure 1d. ..

    Article Title: Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity
    Article Snippet: .. The expression of Integrin α6, Integrin β4, and v-SNARE (all antibodies sourced from Santa Cruz Biotechnology) was analyzed by Western blot. .. Na + /K + ATPase (Cell Signaling Technology) was used as an internal control for protein loading normalization.

    Expressing:

    Article Title: Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity
    Article Snippet: .. The expression of Integrin α6, Integrin β4, and v-SNARE (all antibodies sourced from Santa Cruz Biotechnology) was analyzed by Western blot. .. Na + /K + ATPase (Cell Signaling Technology) was used as an internal control for protein loading normalization.



    Similar Products

    integrin β4  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology integrin β4
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Integrin β4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/Integrin+%CE%B24+Antibody/pmc13025033-274-5-13
    Average 93 stars, based on 1 article reviews
    integrin β4 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    integrin β4  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc integrin β4
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Integrin β4, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/Integrin+beta4+XP+Rabbit+mAb/pm41874446-206-6-49
    Average 95 stars, based on 1 article reviews
    integrin β4 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    β4 integrin fragments  (Kaneka Corp)
    86
    Kaneka Corp β4 integrin fragments
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    β4 Integrin Fragments, supplied by Kaneka Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/anti+fragments+integrin+%CE%B24/10__3390_slash_biom16030417-47-17-20
    Average 86 stars, based on 1 article reviews
    β4 integrin fragments - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    sc 35678 lats1 sirna human santa cruz biotechnology  (Santa Cruz Biotechnology)
    92
    Santa Cruz Biotechnology sc 35678 lats1 sirna human santa cruz biotechnology
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Sc 35678 Lats1 Sirna Human Santa Cruz Biotechnology, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/Integrin+%CE%B24+siRNA/pm41702399-284-52-56
    Average 92 stars, based on 1 article reviews
    sc 35678 lats1 sirna human santa cruz biotechnology - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    β4 integrin  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc β4 integrin
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    β4 Integrin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/pm41590700-179-64-67
    Average 86 stars, based on 1 article reviews
    β4 integrin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti itgb4 antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti itgb4 antibody
    Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and <t>ITGB4</t> expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.
    Anti Itgb4 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/integrin+%CE%B24/Integrin+%CE%B24+Antibody/pmc12666562-134-14-19
    Average 93 stars, based on 1 article reviews
    anti itgb4 antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].

    Journal: Science Advances

    Article Title: Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity

    doi: 10.1126/sciadv.aeb5894

    Figure Lengend Snippet: ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].

    Article Snippet: The expression of Integrin α6, Integrin β4, and v-SNARE (all antibodies sourced from Santa Cruz Biotechnology) was analyzed by Western blot.

    Techniques: Activation Assay, Construct, Expressing, Western Blot, Confocal Microscopy, Incubation, FLAG-tag

    Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and ITGB4 expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.

    Journal: The Journal of Biological Chemistry

    Article Title: A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesis

    doi: 10.1016/j.jbc.2025.110844

    Figure Lengend Snippet: Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and ITGB4 expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.

    Article Snippet: E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection.

    Techniques: Knockdown, Gene Expression, Transfection, Real-time Polymerase Chain Reaction, Expressing, Comparison, Western Blot